Morse 2011.

Methods	Uncontrolled phase I study
Participants	15 ovarian and breast cancer patients with no evidence of disease after prior therapy (ovarian cancer n = 8)
Interventions	Intradermal and subcutaneous short peptides in 2 groups (group 1: APC, HHR6A, BAP31, replication protein A, Abl‐binding protein 3c, cyclin I; group 2: topoisomerase IIα/β, integrin β 8 subunit precursor, CDC2, TACE, g‐catenin, EEDDR1) Adjuvant: Montanide ISA‐51, GM‐CSF
Outcomes	Survival Immune responses: cellular Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Uncontrolled trial
Allocation concealment (selection bias)	High risk	Uncontrolled trial
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’